A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Alzheimer Disease, Healthy

In brief

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B, including a screening period for each part.

Key facts

Study ID
NCT06657768
Run by
Eli Lilly and Company
People needed
128
Starts
2024-10-29
Expected to finish
2027-07-01
Last updated by the study team
2026-06-04

Who can join

Age: 45 and older, up to 85. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.